Literature DB >> 10489037

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.

S J Khoury1, E J Orav, C R Guttmann, R Kikinis, F A Jolesz, H L Weiner.   

Abstract

OBJECTIVE: To study the change in serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble tumor necrosis factor receptors (sTNF-Rs) in MS patients in relation to clinical disease activity and changes on brain MRI.
BACKGROUND: Circulating forms of adhesion molecules or soluble receptors may be released from cells as a consequence of activation and may be useful markers for inflammation.
METHODS: During a prospective longitudinal study over 1 year, 40 patients with MS underwent frequent imaging of the brain (22 MR images per patient) at the time of blood sampling as well as monthly neurologic examinations, and scoring on Kurtzke's Expanded Disability Status Scale (EDSS) and ambulation index (AI).
RESULTS: Patients with relapsing-progressive disease had the highest levels of sICAM-1 whereas patients with progressive disease had the highest levels of sTNF-Rs. Fluctuations in sICAM-1 correlated with the occurrence of attacks in patients with relapsing and relapsing-progressive disease. In patients with relapsing-progressive MS, an increase in sICAM-1 level preceded the appearance of new gadolinium (Gd) enhancing lesions on MRI. In patients with progressive disease, an increase in sTNF-R p55 level preceded the appearance of new Gd enhancing lesions on MRI, whereas a decrease in sICAM-1 levels correlated with the appearance of new Gd enhancing lesions.
CONCLUSIONS: These results demonstrate a linkage between sICAM-1 and sTNF-R levels and disease activity in MS. Furthermore, patients with progressive disease appear to have a different immunologic stage of disease in which immune changes are tightly linked with changes on MRI. The demonstration of a correlation in individual patients between immunologic events and changes in disease activity has implications for monitoring patients undergoing treatment and for monitoring disease progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489037     DOI: 10.1212/wnl.53.4.758

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

Review 2.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

3.  Concentration of soluble adhesion molecules in cerebrospinal fluid and serum of epilepsy patients.

Authors:  Jing Luo; Wei Wang; Zhiqin Xi; Chen Dan; Liang Wang; Zheng Xiao; Xuefeng Wang
Journal:  J Mol Neurosci       Date:  2014-07-08       Impact factor: 3.444

4.  Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.

Authors:  Shlomo Flechter; Tirza Klein; Lea Pollak
Journal:  Neurol Int       Date:  2011-06-15

5.  Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.

Authors:  Rohit Bakshi; Ada Yeste; Bonny Patel; Shahamat Tauhid; Subhash Tummala; Roya Rahbari; Renxin Chu; Keren Regev; Pia Kivisäkk; Howard L Weiner; Francisco J Quintana
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-27

Review 6.  Role of lipoic acid in multiple sclerosis.

Authors:  Hongsheng Xie; Xiufang Yang; Yuan Cao; Xipeng Long; Huifang Shang; Zhiyun Jia
Journal:  CNS Neurosci Ther       Date:  2021-12-28       Impact factor: 5.243

7.  Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.

Authors:  Peter Rieckmann; N Kruse; L Nagelkerken; K Beckmann; D Miller; C Polman; F Dahlke; K V Toyka; H P Hartung; S Stürzebecher
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 8.  The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.

Authors:  Jillian Poles; Elisa Karhu; Megan McGill; H Reginald McDaniel; John E Lewis
Journal:  J Clin Transl Res       Date:  2021-05-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.